Omacetaxine mepesuccinate in the treatment of intractable chronic myeloid leukemia

Yaoyu Chen1
Shaoguang Li2
1Department of Oncology, Novartis Institutes for Biomedical Research, Cambridge, 2Division of Hematology/Oncology, Department of Medicine, University of Massachusetts Medical School, Worcester, MA, USA

Abstract: In a significant proportion of patients with chronic myeloid leukemia, resistance to BCR-ABL tyrosine kinase inhibitors develops due to acquisition of BCR-ABL kinase domain mutations and insensitivity of leukemia stem cells to tyrosine kinase inhibitors. Omacetaxine mepesuccinate (formerly called homoharringtonine) is a natural alkaloid that inhibits protein synthesis and induces cell death. Omacetaxine mepesuccinate has been recently approved by the US Food and Drug Administration to treat patients with chronic myeloid leukemia who failed to respond to multiple tyrosine kinase inhibitors and/or acquired the BCR-ABL-T315I mutation. In this review, we discuss the use and effectiveness of omacetaxine mepesuccinate in the treatment of chronic myeloid leukemia, with coverage of its pharmacology, mode of action, and pharmacokinetics. We believe that omacetaxine mepesuccinate will be beneficial to many patients with chronic myeloid leukemia who do not respond well to tyrosine kinase inhibitors.

Keywords: BCR-ABL, leukemic stem cells, chronic myeloid leukemia, biomarker, hematopoietic stem cells, cancer stem cells

Introduction
Chronic myeloid leukemia (CML) is a myeloproliferative disease induced by the BCR-ABL oncogene. Pathologically, CML patients develop granulocytosis and splenomegaly. CML often begins with a chronic phase, and without proper treatment, the disease progresses to an accelerated phase and ultimately develops into a terminal phase called blast crisis. A hallmark of CML is acquisition of Philadelphia chromosome (Ph), resulting in formation of BCR-ABL. The Ph chromosome is cytogenetically diagnostic of CML. In 1960, Nowell and Hungerford made a landmark discovery of the Ph chromosome and its association with CML. This discovery was the first demonstration of a chromosomal rearrangement that is consistently linked to a specific cancer, and sparked searches for associations of additional chromosomal aberrations with specific forms of cancer. BCR-ABL, the product of the Ph chromosome, has deregulated tyrosine kinase activity, and different forms of BCR-ABL protein with different molecular weights can be generated in patients, depending on the precise breakpoints in the translocation or RNA splicing. The BCR-ABL transcript was shown to contain the first 13 to 14 BCR exons and exons 1 or 2 through 11 of ABL, generating a large mRNA product that, after splicing, encoded an 8.5 kB BCR-ABL chimeric transcript. The fusion of BCR to ABL during translocation increases the tyrosine kinase activity of ABL, and brings new
regulatory domains/motifs to ABL, such as the growth factor receptor-bound protein 2 SH2-binding sites.4–6

CML in accelerated phase and blast crisis is much more diverse and aggressive than chronic phase CML. Over 80% of patients in blast phase have definable genetic aberrations in addition to the Ph chromosome.7 Those genetic aberrations including trisomy 8, i(17q),7,8 loss of p53 function,9,10 MYC amplification,8 RB deletion/rearrangement,11 and p16INK4A (CDKN2) rearrangement/deletion12 have been reported to be associated with blast crisis.

**Treatment of CML**

Before BCR-ABL tyrosine kinase inhibitors (TKIs) were available, allogeneic bone marrow transplantation was the recommended treatment for patients newly diagnosed with CML. The probability of survival and leukemia-free survival of bone marrow transplant recipients at 8 years was 50%–60%, with a low chance of relapse.13,14 After receiving bone marrow transplantation, the majority of long-term survivors could be regarded as operationally “cured”, even if some patients still harbored quiescent leukemia cells.15 In 2001, the first BCR-ABL kinase inhibitor, imatinib mesylate (Gleevec®/Glivec®, formerly STI571; Novartis, Basel, Switzerland), was approved by the US Food and Drug Administration as a first-line standard treatment for CML.16–18 The rate of complete cytogenetic response among patients receiving imatinib was 87% after 5 years of treatment.19 Although it effectively inhibits BCR-ABL kinase activity and improves survival in CML patients, imatinib does not appear to lead to a cure of the disease due to development of point mutations in the ATP binding region of BCR-ABL and the insensitivity of quiescent leukemic stem cells to imatinib. Acquisition of point mutations in the ATP binding region of BCR-ABL has been a major mechanism for development of resistance to imatinib and other BCR-ABL kinase inhibitors. BCR-ABL gene amplification also leads to increased expression of BCR-ABL tyrosine kinase and is associated with drug resistance.20 BCR-ABL-independent resistance mechanisms include effects on drug efflux, import, and binding.21 Further, variations in compound intracellular uptake and retention affect efficacy differences in patients.22 For example, three BCR-ABL mutations (T315I, Y253H, and F317L) have a predicted role in abrogating binding of imatinib to BCR-ABL in resistant patients.23 The second-generation BCR-ABL kinase inhibitor, dasatinib, binds to BCR-ABL with less stringent conformational requirements and was shown to be effective in inhibition of imatinib-resistant mutants.24 Nilotinib is another second-generation BCR-ABL inhibitor and is significantly more potent than imatinib, and also has activity against a number of imatinib-resistant BCR-ABL mutants.25 Compared with imatinib, nilotinib is associated with a reduced incidence of BCR-ABL mutations in patients with newly diagnosed CML in chronic phase.26 Based on a 3-year study, mutations were detected in approximately twice as many patients on imatinib (400 mg once daily) as on nilotinib (300 mg twice daily or 400 mg twice daily).26 Recently, ponatinib, a third-generation TKI, was approved and demonstrated to have remarkable antileukemia activity, particularly in patients with BCR-ABL-T315I mutations that are resistant to other TKIs.27 Ponatinib is a powerful pan-BCR-ABL TKI and is promising for patients with CML or Ph+ acute lymphoblastic leukemia who fail imatinib, dasatinib, and nilotinib.28 It is also active against T315I and other imatinib-resistant mutants.20 However, not all CML patients who are refractory or intolerant to dasatinib or nilotinib are responsive to ponatinib.29 Besides the development of TKI resistance, it has been shown that survival of primitive CML stem cells is not dependent on BCR-ABL kinase activity, and as a result, therapies that aim to inhibit BCR-ABL kinase activity could not eliminate leukemia stem cells in CML.28–31 Thus, a significant number of CML patients will take TKIs for the rest of their lives.32 We have shown that the resistance of leukemia stem cells to imatinib does not appear to involve BCR-ABL kinase domain mutations,33 suggesting that BCR-ABL activates some signaling pathways in a kinase-independent manner in leukemia stem cells.34 Some unique molecular pathways dependent on or independent of BCR-ABL kinase activity were identified to play important roles in the development and survival of leukemia stem cells in CML, including Wnt/β-catenin, Hedgehog, Alox5, PTEN, Src family kinases, and FoxO pathways.33–38 These newly identified genes may serve as potential targets for developing a curative therapy of CML.

Omacetaxine mepesuccinate was recently approved by the US Food and Drug Administration for treating CML patients with resistance or intolerance to two or more TKIs. It is a first-in-class cephalotaxine that has demonstrated efficacy in CML and was shown to produce clinically meaningful responses with acceptable tolerability in patients with chronic phase CML previously treated with two or more TKIs.39 In this paper, we discuss the pharmacology, mode of action, and pharmacokinetics of omacetaxine mepesuccinate, efficacy studies in both patients and animal models of CML, and the safety and tolerability of omacetaxine mepesuccinate as well as its future perspectives.
Pharmacology, mode of action, and pharmacokinetics

Pharmacology

Omacetaxine mepesuccinate is also known as homoharringtonine (HHT) [cephalotaxine, 4-methyl (2R)-2-hydroxy-2-(4-hydroxy-4-methylpentyl) butanedioate (ester)]. It is a natural cephalotaxine alkaloid (Figure 1), and is originally derived from the bark of several cephalotaxus species that are indigenous to Asia (mostly mainland China, and also Japan, Korea, and India). The molecular weight of omacetaxine mepesuccinate is 545.62 (g/mol). Historically, extracts from the bark of cephalotaxus were used in cancer patients by practitioners of traditional Chinese medicine in the Fujian Province of China. However, further development of HHT was hampered by a limited source supply and difficult production for high purity. The successful semisynthesis of HHT by direct esterification of the abundant biosynthetic precursor cephalotaxine was reported in 1999. The development of semisynthetic HHT was paralleled by development of the more convenient subcutaneous route of administration, with pharmacokinetic properties, clinical efficacy, and safety comparable with that of continuous infusion. Semisynthetic HHT is now produced as omacetaxine mepesuccinate (Synribo®, Teva Pharmaceutical Industries Ltd, Petah Tikva, Israel). It is worth mentioning that omacetaxine mepesuccinate is the only effective natural therapeutic agent used in patients with CML.

Mode of action

Omacetaxine mepesuccinate functions as an inhibitor of protein synthesis, mechanistically preventing aminoacyl-tRNA binding to the ribosomal acceptor site and peptide bond formation at the early stage of protein elongation. Omacetaxine mepesuccinate may inhibit the elongation phase of translation by preventing substrate binding to the acceptor site on the 60-S ribosome subunit, leading to blockade of aminoacyl-tRNA binding and peptide bond formation. Further, omacetaxine mepesuccinate was shown to affect diphenylalanine synthesis and puromycin reaction instead of eEF-1-dependent Phe-tRNA-Phe binding, and to exert a significant influence on polypeptide chain elongation.

A recent study showed that omacetaxine mepesuccinate blocks protein synthesis by competing with the amino acid side chains of incoming aminoacyl-tRNAs for binding at the A-site cleft in the peptidyl transferase center.

The mechanism for the antileukemic effect of omacetaxine mepesuccinate is mainly related to induction of apoptosis in leukemia cells (Figure 2). In imatinib-resistant K562 cells, omacetaxine mepesuccinate caused degradation of BCR-ABL proteins by inhibiting heat shock protein 90 in a dose-dependent manner, whereas heat shock protein 70, which mediates the resistance of BCR-ABL-expressing cells to apoptosis, was not changed by treatment with the drug. Omacetaxine mepesuccinate also induced intrinsically apoptotic pathways by activating caspase-9, caspase-8, and caspase-3 and downregulating myeloid cell leukemia-1 (MCL-1) in chronic lymphocytic leukemia and in myeloid leukemia cells. Although downregulation of MCL-1 was
associated with a substantial decrease in viability of K562 cells, loss of MCL-1 did not significantly enhance the efficacy of omacetaxine mepesuccinate in primary B-cells or neutrophils.\(^ {48} \) In BCR-ABL-induced B-cell acute lymphoblastic leukemia, treatment with omacetaxine mepesuccinate slightly reduced the level of nonmutated BCR-ABL proteins, but the level of BCR-ABL-T315I was markedly decreased, indicating that the mutant BCR-ABL is more sensitive to inhibition by omacetaxine mepesuccinate.\(^ {47} \) Interestingly, compared with myeloid leukemia cells, the level of heat shock protein 90 in B-cell acute lymphoblastic leukemia cells was not reduced by treatment with omacetaxine mepesuccinate. The stability of the BCR-ABL-T315I mutant may be more sensitive to treatment with omacetaxine mepesuccinate and depends on alternative oncoprotein chaperones, such as heat shock protein 70 or Hsc70.

Omacetaxine mepesuccinate also had a significant inhibitory effect on leukemia stem cells. In a mouse model of CML, omacetaxine mepesuccinate was shown to greatly reduce the numbers of both leukemia stem cells and total leukemia cells, and treatment of CML mice using both imatinib and omacetaxine mepesuccinate did not further reduce the number of leukemia stem cells or total leukemia cells compared with mice treated using omacetaxine mepesuccinate alone.\(^ {47} \) Omacetaxine mepesuccinate also had a similar inhibitory effect on BCR-ABL T315I-expressing leukemia stem cells compared with nonmutant BCR-ABL expressing leukemia stem cells. On the other hand, when samples from patients with primary CML were tested, omacetaxine mepesuccinate effectively induced apoptosis of primary human CML stem cells (CD34\(^ + \)/CD38\(^ - \)) by downregulation of MCL-1 proteins.\(^ {50} \) In contrast with findings for TKIs, omacetaxine mepesuccinate did not cause accumulation of undivided cells in vitro. Further, the functions of surviving stem cells following treatment with omacetaxine mepesuccinate was significantly reduced in a dose-dependent manner, as determined by a colony-forming assay and the more stringent long-term culture-initiating cell colony assay.\(^ {50} \)

The cytotoxicity of omacetaxine mepesuccinate was thought to be caused by inhibition of cells in the G1 and G2 phases\(^ {52} \) or differentiated noncycling cells,\(^ {51} \) and through reduction in levels of pro-oncogenic or prosurvival proteins through shortening their half-lives, including those of MCL-1, cyclin D1, and c-MYC.\(^ {52} \) Although more mechanistic studies are needed to understand fully the molecular mechanisms by which omacetaxine mepesuccinate suppresses CML cells, the various studies described above have consistently shown that MCL-1 is involved in inhibition of CML cells by omacetaxine mepesuccinate. Identification of other signaling pathways that interact with MCL-1 in CML cells is a logical next step to take in better understanding the mode of action of omacetaxine mepesuccinate.

**Pharmacokinetics**

Omacetaxine mepesuccinate is administered subcutaneously, and maximum concentration in blood is achieved within one hour of injection.\(^ {53} \) Omacetaxine mepesuccinate is primarily hydrolyzed to 4'-DMHHT through plasma esterases with hepatic microsomal oxidative and/or esterase-mediated metabolism.\(^ {53} \) On average, less than 15% of omacetaxine mepesuccinate is excreted unchanged in the urine, and its mean half-life following subcutaneous administration is around 6 hours.\(^ {53} \) To understand its pharmacokinetics, omacetaxine mepesuccinate (1.25 mg/m\(^ 2 \)) was administered subcutaneously twice a day on days 1–14 every 28 days for two cycles, until disease progression or unacceptable toxicity occurred. Blood and urine were collected to measure concentrations of omacetaxine mepesuccinate and its inactive metabolites. Pharmacokinetic parameters were estimated from 21 patients with a diagnosis of relapsed or refractory CML, acute promyelocytic leukemia, acute myeloid leukemia, or myelodysplastic syndrome, or advanced solid tumors who had exhausted or become intolerant to all available therapies.\(^ {53} \) Omacetaxine mepesuccinate is rapidly absorbed and widely distributed, as evidenced by an apparent volume of distribution of 126.8 L/m.\(^ {53} \) Plasma concentration versus time data demonstrated biexponential decay and a mean steady-state terminal half-life of 7 hours. Concentrations of inactive metabolites, 4'-DMHHT and cephaltaxine, were approximately 10% those of omacetaxine mepesuccinate and undetectable in most patients.\(^ {53} \)

The clinical pharmacokinetics of omacetaxine mepesuccinate was similarly studied in eight patients who received uniformly labeled omacetaxine mepesuccinate at 3–4 mg/m\(^ 2 \) by continuous 6-hour infusion.\(^ {54} \) Unchanged omacetaxine mepesuccinate declined biphasically in plasma, with an \( \alpha \)-half-life of 0.5±0.1 hours and a \( \beta \)-half-life of 9.3±1.4 hours. The total clearance of omacetaxine mepesuccinate was 177.4±27.7 mL/hour × kg, and the apparent volume of distribution, estimated from the area under the drug concentration versus time curve, was 2.4±0.4 L/kg.\(^ {54} \)

Omacetaxine mepesuccinate is mainly metabolized in the liver, but does not cause clinical liver toxicity.\(^ {53} \) A major metabolite of omacetaxine mepesuccinate was identified as omacetaxine mepesuccinate acid, which was 700 times less toxic than omacetaxine mepesuccinate. Urinary excretion of unchanged omacetaxine mepesuccinate accounted for 15% of the dose.\(^ {53} \) The major drug-related adverse effects
included thrombocytopenia (48%) and neutropenia (33%). Although omacetaxine mepesuccinate appears to have more side effects than TKIs, it has a unique activity against TKI-insensitive CML stem cells (see below), making it a useful therapeutic agent in some patients who have failed to respond to TKIs.

**Efficacy studies**

**Efficacy of omacetaxine mepesuccinate in treating CML**

Omacetaxine mepesuccinate has been studied using BCR-ABL-expressing myeloid and lymphoid cell lines and mouse models of CML and B-cell acute lymphoblastic leukemia induced by nonmutant BCR-ABL or mutant BCR-ABL-T315I. It is exciting to see that more than 90% of leukemia stem cells are killed after treatment with omacetaxine mepesuccinate in vitro. Omacetaxine mepesuccinate effectively caused reduction of leukemia cells in CML and mice with B-cell acute lymphoblastic leukemia. Omacetaxine mepesuccinate also inhibited BCR-ABL T315I-expressing leukemia stem cells.

Omacetaxine mepesuccinate was initially used in the early 1980s to treat CML patients in the People’s Republic of China, and two clinical studies later showed that omacetaxine mepesuccinate was an effective treatment for CML, as shown by induction of hematologic remission for longer than 12 months in the majority of patients in chronic phase. In a Phase I/II study of subcutaneous administration of omacetaxine mepesuccinate in CML patients who had failed prior therapy, efficacy and good tolerance were observed for omacetaxine mepesuccinate, and could be achieved when the same doses were administered by intravenous injection. The maximal tolerated dose was 1.25 mg/m² subcutaneously twice daily. Six patients (median age 53 years) who had failed imatinib were treated with omacetaxine mepesuccinate, and five turned out to be evaluable. Among the five patients, a complete hematologic response (CHR) was achieved in all patients and three patients had a cytogenetic response (one complete and two minor). In two patients who were found to have BCR-ABL kinase domain mutations at the start of treatment with omacetaxine mepesuccinate, a cytogenetic response were achieved and accompanied by no detectable BCR-ABL mutations. The efficacy of omacetaxine mepesuccinate was assessed further in a Phase II study of CML patients with the BCR-ABL-T315I mutation. In total, 62 patients received a median of seven cycles of omacetaxine mepesuccinate. A CHR was achieved in 48 of these patients and their median response duration was 9.1 months. Fourteen patients achieved a major cytogenetic response, including a complete cytogenetic response in ten patients (16%). Median progression free-survival in this trial was 7.7 months.

So far, a couple of Phase II studies have been conducted to test HHT/omacetaxine mepesuccinate either alone or in combination with other antitumor agents in 828 CML patients with different disease stages (Tables 1 and 2). Four single-agent Phase II studies tested the efficacy of HHT/omacetaxine mepesuccinate in early or late chronic phase CML patients. In total, 212 CML patients were treated with HHT (2.5 mg/m²×14 days) or omacetaxine mepesuccinate (1.25 mg/m² twice/day×14 days). The average CHR was 80%, and 42% of patients achieved a cytogenetic response. Four single-agent Phase II studies demonstrated the effectiveness of omacetaxine mepesuccinate in treating CML patients resistant or intolerant to two or more TKIs. A total of 252 CML patients were treated with omacetaxine mepesuccinate (1.25 mg/m² twice daily, 28 days cycle for induction, ≤7 days/cycle as maintenance), and the average cytogenetic response rate was 20.5%.

Omacetaxine mepesuccinate were also tested in combination with other active agents. Two Phase II trials tested the efficacy of omacetaxine mepesuccinate (1.25 mg/m² twice daily×14 days) combined with imatinib in 24 patients with chronic phase CML. The average CHR of drug-treated patients was 66%. Fifty percent of these patients achieved a cytogenetic response. Four Phase II trials tested the effect of a combination of HHT 2.5 mg/m² and ara-C in 202 patients with chronic phase CML. The average CHR was 81%. One Phase II trial tested the effect of HHT

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Summary of OM related clinic trials</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Therapy</strong></td>
<td><strong>Trials</strong></td>
</tr>
<tr>
<td>HHT/OM</td>
<td>8</td>
</tr>
<tr>
<td>OM + Imatinib</td>
<td>2</td>
</tr>
<tr>
<td>HHT + ara-C</td>
<td>4</td>
</tr>
<tr>
<td>HHT + IFN-α</td>
<td>1</td>
</tr>
<tr>
<td>OM + Imatinib + G-CSF</td>
<td>1</td>
</tr>
<tr>
<td>HHT + IFN-α + ara-C</td>
<td>1</td>
</tr>
</tbody>
</table>

**Abbreviations:** CML, chronic myeloid leukemia; CHR, complete hematologic response; HHT, homoharringtonine; OM, Omacetaxine mepesuccinate; Ara-C, arabinofuranosyl cytidine; IFN-α, interferon-alpha; G-CSF, granulocyte colony-stimulating factor; CP, chronic phase; ND, not determined.
Table 2 Summary of current CML treatment

<table>
<thead>
<tr>
<th>Name</th>
<th>Function</th>
<th>Mechanism of action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Imatinib</td>
<td>BCR-ABL kinase inhibitor</td>
<td>Specific for the tyrosine kinase domain in ABL, c-Kit and PDGF-R</td>
</tr>
<tr>
<td>Dasatinib</td>
<td>BCR-ABL kinase inhibitor</td>
<td>Targeting ABL, Src, c-Kit, ephrin receptors and seroveral tyrosine kinases</td>
</tr>
<tr>
<td>Nilotinib</td>
<td>2nd generation BCR-ABL</td>
<td>Targeting ABL, LCK, c-Kit, EPHA3, EPHA8, DDR1, DDR2, PDGF-R, MAPK11 and ZAK</td>
</tr>
<tr>
<td></td>
<td>BCR-ABL kinase inhibitor</td>
<td></td>
</tr>
<tr>
<td>Ponatinib</td>
<td>3rd generation BCR-ABL</td>
<td>Targeting BCR-ABL with or without T3151 mutation</td>
</tr>
<tr>
<td></td>
<td>BCR-ABL kinase inhibitor</td>
<td></td>
</tr>
<tr>
<td>Ara-C</td>
<td>Cytarabine or cytosine</td>
<td>Interfering with DNA synthesis</td>
</tr>
<tr>
<td></td>
<td>arabinoside</td>
<td></td>
</tr>
<tr>
<td>IFN-α</td>
<td>Interferon α</td>
<td>Selective toxicity against the leukemic clone; enhancement of “immune” regulation; modulation of bone marrow microenvironment regulation of hematopoiesis</td>
</tr>
<tr>
<td>G-CSF</td>
<td>Granulocyte colony</td>
<td>Overcome imatinib mesylate-induced neuropenia as myelosuppression</td>
</tr>
<tr>
<td></td>
<td>stimulating factor</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: Ara-C, arabinofuranosyl cytidine; IFN-α, interferon-alpha; G-CSF, granulocyte colony-stimulating factor.

2.5 mg/m² combined with interferon-α in 37 patients with early chronic phase CML. The average CHR was 89%, with 57% of patients achieving a cytogenetic response. One Phase II trial tested the effect of omacetaxine mespeuccinate combined with imatinib and granulocyte colony-stimulating factor in eleven patients with blast phase CML. The average CHR was 61%, and 100% of patients achieved a cytogenetic response. Another Phase II trial tested the effect of a combination of HHT, interferon-α, and ara-C in 90 patients with early chronic phase CML. The average CHR was 94%, and 74% of patients achieved a cytogenetic response.

Efficacy of omacetaxine mespeuccinate in other blood malignancies

In addition to being used to treat CML, omacetaxine mespeuccinate has also been used to treat other types of blood malignancy, such as myelodysplastic syndrome, acute myeloid leukemia, and multiple myeloma. Although CML is the focus of this review, we believe that it would be beneficial if we also discuss, at least briefly, other diseases in which omacetaxine mespeuccinate has a therapeutic effect.

In a study using HHT at a dose of 5 mg/m² by 24-hour continuous infusion for 9 days in 28 patients (16 with myelodysplastic syndrome, 12 with myelodysplastic syndrome/acute myeloid leukemia), a 28% overall response rate (8/28) was achieved, with complete remission in seven patients and partial remission in one patient. In another Phase II pilot study of HHT in myelodysplastic syndrome, HHT was given at a dose of 2.5 mg/m² via continuous infusion for 7 days and maintenance every 4 weeks. One patient (11%) responded with a CHR and cytogenetic remission after one course and eight patients did not respond. Similarly, the effect of omacetaxine mespeuccinate was tested in patients with acute myeloid leukemia. HHT was evaluated at a dose of 5 mg/m² by continuous infusion daily for 9 days in 66 patients with relapsed/refractory acute myeloid leukemia or blastic phase CML. Seven of 43 patients with relapsed acute myeloid leukemia achieved a complete remission (16%). Two of three patients primarily resistant to low-dose cytarabine also achieved complete remission, while eleven patients with acute myeloid leukemia primarily resistant to an anthracycline-cytarabine combination did not respond. The effect of omacetaxine mespeuccinate was also shown to have a stronger effect on acute myeloid leukemia when combined with other therapeutic agents such as cytarabine, aclacinocibin, or granulocyte-colony stimulating factor.

The efficacy of omacetaxine mespeuccinate was also studied in multiple myeloma. Omacetaxine mespeuccinate significantly inhibited proliferation of human multiple myeloma cell lines and tumor cells from patients with relapsed refractory multiple myeloma in a dose-dependent manner. Omacetaxine mespeuccinate further reduced the levels of cellular FLICE-like inhibitory protein, activated caspase-8, and induced active truncated-Bid in multiple myeloma cells, including RPMI8226 and U266. When combined with other antitumor agents, omacetaxine mespeuccinate enhanced the efficacy of melphalan, bortezomib, and ABT-737. The cytotoxicity of omacetaxine mespeuccinate was related to downregulation of AKT phosphorylation/activation and various substrates of AKT, including nuclear factor kappa B, XIAP, and cIAP, and cyclin D1.

Safety and tolerability

Myelosuppression and nonhematologic toxicity

Myelosuppression is a major dose-related side effect of omacetaxine mespeuccinate. In CML patients treated with omacetaxine mespeuccinate alone or in combination with TKIs or other agents, intravenous administration of omacetaxine mespeuccinate caused granulocytopenia (<0.5×10⁹/L) in 27%–39% of patients, and thrombocytopenia (30×10⁹/L) in 13%–25% of patients. Myelosuppression is also the principal side effect with subcutaneous administration of omacetaxine mespeuccinate.

The most common nonhematologic toxicities in CML patients treated with omacetaxine mespeuccinate include
Omacetaxine mepesuccinate in intractable CML

Diarrhea, fatigue, pyrexia, nausea, asthenia, headache, anorexia, hyperglycemia, injection site erythema, and tachycardia/chest pain. \(^{59,60,82-85}\) Recently, a pooled safety analysis in patients with TKI-resistant CML treated using subcutaneous omacetaxine mepesuccinate (1.25 mg/m\(^2\)) showed an acceptable safety profile in all phases of CML. \(^{85}\) Adverse events were primarily hematologic, and grade 3/4 nonhematologic adverse events were uncommon. \(^{85}\) However, a concern is the potential adverse effects in patients after long-term use of omacetaxine mepesuccinate. It is likely that some patients may not tolerate these adverse effects, and need to switch to other therapies. On the other hand, some patients may benefit from this treatment, simply because they have run out of therapeutic options and the drug is effective. Further, in contrast with TKIs, omacetaxine mepesuccinate has an inhibitory activity against leukemia stem cells, making it an attractive therapy for being close to curing the disease.

**Potential use of omacetaxine mepesuccinate**

Imatinib at 400 mg daily is the standard of care for patients with CML in chronic phase, and dasatinib and nilotinib represent alternatives that have replaced imatinib as first-line therapy in patients with imatinib resistance or intolerance. \(^{19,86-88}\) Clearly, omacetaxine mepesuccinate will not substitute for imatinib and other TKIs. However, omacetaxine mepesuccinate has a unique role in certain patients with CML. First, because omacetaxine mepesuccinate primarily targets signaling molecules downstream of BCR-ABL and has a unique mode of action, it could be a choice for patients carrying BCR-ABL mutation and resistant to TKIs, because some patients including BCR-ABL-T315I carriers do not respond to available TKIs. For these patients, omacetaxine mepesuccinate could be used as a single agent for treating CML. Second, TKIs do not eradicate the leukemia stem cells that initiate CML. Finally, omacetaxine mepesuccinate has been shown to have an inhibitory effect on leukemia stem cells in preclinical models. \(^{57,59}\) Therefore, omacetaxine mepesuccinate should be used in combination with a TKI. A recent study showed that omacetaxine mepesuccinate in combination with nilotinib led to undetectable residual disease at a molecular level in an imatinib-resistant CML patient harboring the BCR-ABL-T315I mutation. \(^{89}\) As the third-generation TKI ponatinib came to the market and responses were observed in highly refractory patients with either no mutations or other mutations resistant to first- or second-generation FDA approved TKIs. \(^{20}\) Thus, a combinatorial therapeutic strategy using omacetaxine mepesuccinate and a new-generation TKI would be an attractive approach in helping to cure CML.

In fact, omacetaxine mepesuccinate has been shown to be effective in treating CML as a single agent\(^{87,58,60,62}\) and in combination with imatinib, \(^{58,90}\) interferon-\(\alpha,\) \(^{70}\) cytarabine, \(^{58,69}\) and both interferon-\(\alpha\) and cytarabine. \(^{72}\)

**Conclusion**

After the US Food and Drug Administration granted accelerated approval for omacetaxine mepesuccinate (Synribo) in the treatment of adult patients in CML chronic phase or accelerated phase with resistance and/or intolerance to two or more TKIs, its effectiveness in treating these patients has been observed. In addition, omacetaxine mepesuccinate has been shown to have inhibitory activity in TKI-insensitive CML stem cells, suggesting that this agent in combination with TKIs provides a curative therapeutic strategy for CML patients.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


64. Akard LP KH, Nicolini FE, et al. Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors. Haematologica. 2013;98(7):c78–c79.


